Voyager Therapeutics (VYGR) Capital Expenditures (2014 - 2026)
Voyager Therapeutics (VYGR) posted Capital Expenditures of $14000.0 for Q1 2026, up 100.91% sequentially from -$1.5 million in Q4 2025, and down 97.87% YoY from $658000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Capital Expenditures (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Capital Expenditures for 13 years, with the latest figure at $14000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 97.87% year-over-year to $14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$217000.0 (down 105.21% YoY) and the FY2025 annual result came in at $427000.0, down 87.87% from the prior year.
- Capital Expenditures grew to $14000.0 in Q1 2026 per VYGR's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.1 million in Q2 2024 and troughed at -$1.5 million in Q4 2025.
- A 5-year average of $571117.6 and a median of $258000.0 in 2024 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 4286.67% in 2025, down 1095.48% in 2025.
- Over 5 years, Capital Expenditures stood at $933000.0 in 2022, then declined by 19.08% to $755000.0 in 2023, then sank by 79.47% to $155000.0 in 2024, then plunged by 1095.48% to -$1.5 million in 2025, then surged by 100.91% to $14000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $14000.0, -$1.5 million, and $207000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 251.02 Mn |
| 10 | Voyager Therapeutics | 201.93 Mn | 85.59 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | -1.54 Mn |
| Dec 31, 2025 | -1.54 Mn |
| Sep 30, 2025 | 207,000.00 |
| Sep 30, 2025 | 207,000.00 |
| Jun 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 658,000.00 |
| Mar 31, 2025 | 658,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | 258,000.00 |
| Sep 30, 2024 | 258,000.00 |
| Jun 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 3.09 Mn |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |